In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Neoprobe/USSC

This article was originally published in The Gray Sheet

Executive Summary

Neoprobe/USSC: Firms terminate marketing agreement for Neoprobe's RIGS surgical cancer detection/lymphatic mapping products. Neoprobe and U.S. Surgical Corp. co-developed the technology under a September 1996 agreement which called for USSC to pay the majority of a $5.5 mil. investment to Neoprobe upon U.S. and European approval of the first product, the RIGScan CR49 for colorectal cancer detection, in exchange for receiving exclusive worldwide sales rights (excluding Korea, Thailand, Taiwan and Singapore). A biologics licensing application for the RIGScan CR49, submitted by Neoprobe last December, has yet to be approved by FDA ("The Gray Sheet" July 21, I&W-5)...

You may also be interested in...



Neoprobe Planning RIGS Colorectal Cancer Detection Phase III Trial With FDA

Neoprobe will meet with FDA in late summer to discuss a proposed Phase III trial protocol for its RIGS technology for colorectal cancer detection

QUOTED. 10 April 2020. Shawn Patterson.

3D-printing company Carbon and in vitro diagnostics maker Resolution Medical announced plans to manufacture more than one million 3D-printed nasal swabs per week to test for COVID-19. See what Resolution Medical’s president Shawn Patterson said about it here.

UsernamePublicRestriction

Register

MT009060

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel